Clinical Trial Update: Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial is planned to evaluate the combination of Tagraxofusp and Pacritinib in patients with intermediate-1 or higher myelofibrosis who have had…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Pacritinib (pacritinib)
• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Myelofibrosis，MF | EARLY_Phase 1 | Status: NOT_YET_RECRUITING